Title |
Combining PARP Inhibition with Platinum, Ruthenium or Gold Complexes for Cancer Therapy
|
---|---|
Published in |
ChemMedChem, September 2020
|
DOI | 10.1002/cmdc.202000391 |
Pubmed ID | |
Authors |
Nur Aininie Yusoh, Haslina Ahmad, Martin R. Gill |
Abstract |
Platinum drugs are heavily used first-line chemotherapeutic agents for many solid tumours and have stimulated substantial interest in the biological activity of DNA-binding metal complexes. These complexes generate DNA lesions which trigger the activation of DNA damage response (DDR) pathways that are essential to maintain the genomic integrity. Cancer cells exploit this intrinsic DNA repair network to counteract many types of chemotherapies. Therefore, advances in the molecular biology of cancer has paved the way for the development of DDR inhibitors, especially the poly (ADP-ribose) polymerase (PARP) inhibitors (PARPi). Now, it has emerged that agents which induce high levels of DNA replication stress or single-strand break damage can be combined with PARPi for potent synergy and has potential to improve disease outcomes specifically in advanced cancer patients. In this review, we summarize early-stage, preclinical and clinical findings of work exploring platinum and emerging ruthenium anti-cancer complexes in combination with PARPi. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United Kingdom | 5 | 29% |
Germany | 4 | 24% |
Portugal | 1 | 6% |
India | 1 | 6% |
Sweden | 1 | 6% |
Unknown | 5 | 29% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Scientists | 10 | 59% |
Members of the public | 7 | 41% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 36 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 10 | 28% |
Student > Bachelor | 4 | 11% |
Researcher | 3 | 8% |
Other | 2 | 6% |
Professor | 1 | 3% |
Other | 3 | 8% |
Unknown | 13 | 36% |
Readers by discipline | Count | As % |
---|---|---|
Biochemistry, Genetics and Molecular Biology | 9 | 25% |
Chemistry | 7 | 19% |
Neuroscience | 2 | 6% |
Agricultural and Biological Sciences | 1 | 3% |
Veterinary Science and Veterinary Medicine | 1 | 3% |
Other | 2 | 6% |
Unknown | 14 | 39% |